Today: 7 February 2026
Subscribe
Browse Category

Health News News 18 December 2025 - 2 February 2026

ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday

ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday

ImmunityBio shares fell 12.1% to $6.45 Friday after the company previewed new data from its Phase 2 glioblastoma trial, with full results due Jan. 31. The stock traded heavily between $7.88 and $6.43. Median overall survival in the study was “not yet reached” as of Jan. 22, with 19 of 23 patients alive. Investors are watching for more details on durability, safety, and trial design.
25 January 2026
·····
Eli Lilly stock set for Tuesday spotlight as new obesity-pill data ripples through GLP-1 trade

Eli Lilly stock set for Tuesday spotlight as new obesity-pill data ripples through GLP-1 trade

Eli Lilly shares rose 0.5% to $1,038.40 Friday, ahead of a holiday-shortened week. Traders are watching early U.S. prescription numbers for Novo Nordisk’s new oral Wegovy, which logged 3,071 scripts in its debut, just below Lilly’s Zepbound. U.S. markets reopen Tuesday, with investors eyeing fresh demand signals and pricing risks. About 3.8 million Lilly shares traded Friday.
19 January 2026
···
Why ImmunityBio stock is surging today: ANKTIVA sales jump and a key bladder-cancer trial nears the finish line

Why ImmunityBio stock is surging today: ANKTIVA sales jump and a key bladder-cancer trial nears the finish line

ImmunityBio shares jumped 16.5% to $4.60 Friday after the company reported $113 million in preliminary 2025 net product revenue from ANKTIVA and disclosed accelerated approvals in Saudi Arabia for lung and bladder cancer uses. Trading volume topped 56 million shares. Enrollment in the company’s pivotal bladder-cancer trial surpassed 85%, with FDA filing planned by late 2026.
16 January 2026
···
Costco Canada recall expands: Peace by Chocolate pistachio chocolates pulled over salmonella risk

Costco Canada recall expands: Peace by Chocolate pistachio chocolates pulled over salmonella risk

Costco Canada recalled certain Peace by Chocolate gift boxes sold online after a supplier warned of possible Salmonella in two pistachio chocolates. The recall affects products bought on Costco.ca between Sept. 7 and Dec. 3, with no reported illnesses as of Jan. 8. Canada’s pistachio recall list now covers over 330 products. The CFIA says its investigation is ongoing and more recalls may follow.
9 January 2026
·
Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

Merck shares slipped 0.2% in after-hours trading after U.S. health officials cut HPV vaccine guidance to one dose, raising concerns over Gardasil sales. Analysts warned the change could reduce 2026 Gardasil revenue by up to $630 million. Merck also completed its $9.2 billion Cidara acquisition and set Feb. 3 for quarterly results.
8 January 2026
····
Novo Nordisk (NVO) stock jumps as $149 Wegovy pill rollout puts pricing in the spotlight

Novo Nordisk (NVO) stock jumps as $149 Wegovy pill rollout puts pricing in the spotlight

Novo Nordisk’s U.S.-listed shares rose 4.7% to $57.71 Tuesday after launching oral Wegovy for self-pay patients at $149 a month for starter doses. The pill is now available at major pharmacies and through telehealth. Investors await early demand data and updates from a key healthcare conference on Jan. 13. Rival Eli Lilly expects a regulatory decision on its own weight-loss pill in March.
6 January 2026
···
Novo Nordisk stock jumps premarket as $149 Wegovy pill hits U.S. market

Novo Nordisk stock jumps premarket as $149 Wegovy pill hits U.S. market

Novo Nordisk’s U.S.-listed shares rose about 4% in premarket trading after the company launched an oral version of its Wegovy weight-loss drug, priced from $149 a month for some cash-paying patients. The stock traded at $57.29, up from $55.11. Investors are watching early demand and await the company’s February 4 results for margin outlook. The launch comes amid restructuring and job cuts at Novo’s U.S. operations.
6 January 2026
···
Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

Viking Therapeutics shares fell 9.9% to $31.93 Monday after Novo Nordisk launched its Wegovy weight-loss pill in the U.S. with starter doses priced at $149 per month for cash-pay patients. Novo’s U.S.-listed shares rose 5.1%, while Eli Lilly dropped 3.9%. Viking’s next updates include Phase 3 trial milestones in Q1 and an earnings release expected Feb. 4.
5 January 2026
·····
Arrowhead Pharmaceuticals stock slides despite Health Canada approval of Redemplo — what investors watch next

Arrowhead Pharmaceuticals stock slides despite Health Canada approval of Redemplo — what investors watch next

Arrowhead Pharmaceuticals shares fell 6.9% to $63.11 Monday after Health Canada approved Redemplo, its triglyceride-lowering drug for familial chylomicronemia syndrome. The stock dropped despite the clearance, tracking weakness across biotech stocks. Investors now await Arrowhead’s obesity data webinar on Jan. 6 and its J.P. Morgan conference presentation Jan. 12.
5 January 2026
···
Tesco issues urgent “do not eat” recall for three pate lines after date-label error

Tesco issues urgent “do not eat” recall for three pate lines after date-label error

LONDON, January 4, 2026, 13:02 ET Britain’s Tesco has recalled three 170-gram own-brand pate products after they were labelled with an incorrect use-by date, prompting a warning over a possible microbiological risk, the UK’s Food Standards Agency said on Jan. 3. The recall covers Tesco Coarse Farmhouse Pate, Coarse Ardennes Pate and Smooth Chicken Liver Pate with a use-by date of 05 January 2026. Food Standards Agency Use-by dates are safety deadlines for foods that spoil quickly, and the watchdog warns people should not eat food after that date even if it looks and smells normal. Mislabelled dates can leave
4 January 2026
·
Bupa renews ParalympicsGB partnership and seals Nuffield Health deal as robotic knee surgery hits 1,000 mark

Bupa renews ParalympicsGB partnership and seals Nuffield Health deal as robotic knee surgery hits 1,000 mark

NEW YORK, January 1, 2026, 06:51 ET Bupa UK on Wednesday renewed its role as Official Healthcare Partner of ParalympicsGB and agreed a new three-year contract between Bupa UK Insurance and Nuffield Health, the company said. The Nuffield agreement adds direct appointment booking and wider access to diagnostics for Bupa customers. (Source) The moves matter because speed to diagnosis is a selling point in private healthcare, where delays between referral, scans and treatment can drive customer frustration. Bupa is also tying its brand to elite sport at a time when sponsors are under pressure to show measurable health outcomes. For
1 January 2026
Axsome stock jumps nearly 23% after FDA fast-tracks AXS-05 for Alzheimer’s agitation

Axsome stock jumps nearly 23% after FDA fast-tracks AXS-05 for Alzheimer’s agitation

NEW YORK, December 31, 2025, 19:19 ET — After-hours Axsome Therapeutics, Inc. shares jumped 22.9% to $182.64 in after-hours trading on Wednesday after the company said the U.S. Food and Drug Administration accepted its supplemental New Drug Application for AXS-05 to treat agitation linked to Alzheimer’s disease and granted it Priority Review. The agency set an April 30, 2026 target action date, and CEO Herriot Tabuteau said “up to 76% of people with Alzheimer’s disease experience agitation.” GlobeNewswire The decision matters because Priority Review shortens the FDA’s review timeline, pulling a key regulatory catalyst forward for investors who have been
1 January 2026
···
Structure Therapeutics (GPCR) Stock News and Forecasts on Dec. 23, 2025: Oral Obesity Pipeline, Capital Raise, Analyst Targets, and What Comes Next

Structure Therapeutics (GPCR) Stock News and Forecasts on Dec. 23, 2025: Oral Obesity Pipeline, Capital Raise, Analyst Targets, and What Comes Next

Structure Therapeutics Inc. (NASDAQ: GPCR) is ending 2025 in the middle of one of biotech’s hottest battlegrounds: oral weight-loss medicines. As of Dec. 23, 2025, GPCR shares were trading around $67.50 in U.S. session data, after a volatile stretch driven by blockbuster obesity-trial headlines, a major equity financing, and a wave of analyst price-target updates. Below is a comprehensive roundup of the latest news, forecasts, and analysis available as of 23.12.2025, and what investors are watching next. What is Structure Therapeutics, and why does GPCR trade like a headline detector? Structure Therapeutics is a clinical-stage biopharmaceutical company developing oral small-molecule
23 December 2025
····
FDA Approves Wegovy Pill: Novo Nordisk’s Oral Semaglutide Launch Ignites a 2026 Weight‑Loss Drug Showdown

FDA Approves Wegovy Pill: Novo Nordisk’s Oral Semaglutide Launch Ignites a 2026 Weight‑Loss Drug Showdown

On December 22, 2025, Novo Nordisk won one of the most consequential regulatory decisions in modern obesity medicine: U.S. FDA approval of a once‑daily “Wegovy pill” (oral semaglutide 25 mg) for chronic weight management—marking the first oral GLP‑1 authorized in the U.S. specifically for weight loss. Novo Nordisk+1 For Novo Nordisk, the milestone is more than a product expansion. It’s a high‑stakes move to defend its GLP‑1 franchise, widen access beyond injections, and reassert momentum after a volatile year in which investors questioned its growth trajectory and competitive positioning. Reuters+1 What the FDA approved on December 22, 2025 The Wegovy
23 December 2025
··
So Delicious Dairy Free Ice Cream Recall: Danone Pulls Salted Caramel Cluster Pints Over Possible “Small Stones” (Dec. 17, 2025)

So Delicious Dairy Free Ice Cream Recall: Danone Pulls Salted Caramel Cluster Pints Over Possible “Small Stones” (Dec. 17, 2025)

December 17, 2025 — If you keep dairy-free frozen treats stocked for the holidays, it’s worth taking a quick look in your freezer. Danone U.S. has issued a voluntary nationwide recall for specific pints of So Delicious Dairy Free Salted Caramel Cluster after the company warned the product may contain foreign materials — including small stones and other hard objects — in the cashew pieces mixed into the dessert. U.S. Food and Drug Administration+1 The recall, which was posted by the U.S. Food and Drug Administration (FDA) as a company announcement, applies to a single So Delicious flavor and pint
18 December 2025
·
1 2 3

Stock Market Today

Walmart stock jumps 3% to $131 as Dow clears 50,000 — what to watch before Monday

Walmart stock jumps 3% to $131 as Dow clears 50,000 — what to watch before Monday

7 February 2026
Walmart shares climbed 3.34% to $131.18 Friday, pushing its market value to about $1.05 trillion as the Dow closed above 50,000 for the first time. Retail stocks mostly gained, with Target up 4.24% and Costco up 1.20%, while Amazon dropped 5.55%. Investors await Walmart’s fiscal Q4 results on Feb. 19 and key U.S. economic data next week.
Go toTop